With a market capitalization of $18.4 billion and an impressive EBITDA of $1.69 billion in the last twelve months, ICON's position as a key player in accelerating drug development for biopharma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback